Cancer SurgeryPREHABNCT07389746
Preoperative Physical Exercise, Nutritional Support, and Psychological Intervention (Multimodal Prehabilitation) to Strengthen Patients' Overall Health and Reduce Postoperative Complications
A study testing Multimodal Prehabilitation in people with Cancer Surgery and Prehabilitation, run by University Hospital of Cologne at 1 site in Germany.
Trial summary
In this prospective, randomized, controlled trial patients undergoing major gastrointestinal cancer surgery will be exercised (intervention group) 4 weeks before surgery with a high-intensity interval training (HIIT). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cancer Surgery, Prehabilitation
- What is being tested?
- Multimodal Prehabilitation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jul 2026to 1 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Candidate to elective major gastrointestinal cancer surgery (pelvic exenteration, cytoreductive surgery, oesophagectomy, transhiatal gastrectomy, hepatectomy, pancreatectomy, rectum resection)
- High risk for surgical complications defined by presence of comorbid disease such as deconditioning, heart disease, diabetes, renal impairment or morbid obesity
- Duke Activity Status Index score (DASI) <402
- Schedule allowing for at least 4 weeks for intervention with multimodal prehabilitation prior to surgery / willingness to exercise
Who cannot join
- Non-elective surgery
- Unstable cardiac or respiratory disease
- Locomotor limitations precluding exercise training
- Cognitive deterioration impeding adherence to the programme
- Enrolment in other research studies affecting study endpoint
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site
University Hospital of Cologne
Cologne, 50931
Tobias Kammerer, Professor, 0049-179-5286891, tobias.kammerer@uk-koeln.de
About this study
Official title: Multimodal Prehabilitation Reduces Postoperative Complications in High Risk Patients Undergoing Major Gastrointestinal Cancer Surgery
In this prospective, randomized, controlled trial patients undergoing major gastrointestinal cancer surgery will be exercised (intervention group) 4 weeks before surgery with a high-intensity interval training (HIIT). They will also receive a specialized nutrition therapy and psychological support (multimodal prehabilitation). Aim of this study is to find out if the prehabilitation group is more resilient to postoperative complications when compared to the control group that will receive standard of care. Another goal is to unravel the underlying mechanisms that are stimulated by exercise like enhancing vascular function, improving immune system response, strengthen cellular tumor defense and optimizing neurological outcome.
Read the detailed description
Postoperative complications leading to death represent the third leading cause of mortality worldwide, equating to roughly one in 13 deaths and forming what has been termed a hidden pandemic. Analysis of the ACS NSQIP database further illustrates this impact, revealing that 19% of surgical patients had not returned home within 30 days. The severity of these complications is strongly associated with long-term survival outcomes. However, for individuals with advanced or recurrent gastrointestinal cancers-including pelvic, peritoneal, oesophageal, hepatic, gastric, and pancreatic disease-complete surgical resection remains the sole potentially curative treatment. In Germany alone, approximately 85,000 patients undergo major gastrointestinal cancer surgery annually, making complication reduction a key clinical goal. This multicenter German trial is the first to comprehensively integrate exercise, nutrition, psychological support, and patient education into a modern multimodal prehabilitation strategy.
The main outcome measure of this trial is the incidence of severe postoperative complications defined as Clavien-Dindo grade III-V. The central hypothesis is that prehabilitation decreases postoperative complications and thus improves prognosis and survival. The intended study population includes patients with substantial comorbidities who face a high risk of complications, elevated healthcare costs, and poor cancer outcomes, often due to impaired physiological fitness and failure to complete intended oncological therapy.
Inclusion criteria are:
- age ≥18/ ≤80 years
- elective major abdominal cancer surgery (pelvic exenteration, cytoreductive surgery, oesophagectomy, transhiatal gastrectomy, hepatectomy, pancreatectomy, rectum resection)
- Duke Activity Status Index (DASI) score <40
- high risk for surgical complications: => presence of comorbid disease as one or more of the following:
- known or documented history of coronary artery disease
- known or documented history of heart failure or brain-derived natriuretic peptide (BNP) >400pg/mL
- high risk of pulmonary complications as documented by Ariscat score >4434
- diabetes currently treated with an oral hypoglycemic agent and/or insulin
- preoperative serum creatinine >200 μmol/l
- morbid obesity with body mass index (BMI) ≥35 kg/m2
- preoperative deconditioning as confirmed by six-minute walk test (6-MWT) <400 meters or by cardiopulmonary exercise testing (CPET) derived parameters (either anaerobic threshold (if done) <12 ml/kg/min, peak oxygen consumption (VO2) <16 mL/kg/min, peak VO2<710 mL/m2, or Ve/VCO2 [ventilator equivalents for carbon dioxide] >35)
- schedule allowing for at least 4 weeks for intervention with multimodal prehabilitation prior to surgery and patient's willingness to exercise
Exclusion criteria are:
- non-elective surgery
- unstable cardiac or respiratory disease
- locomotor limitations precluding exercise training, including severe deconditioning and frailty as reflected by inability to complete CPET test or peak VO2 <10 ml/kg/min
- cognitive deterioration impeding adherence to the programme
The prehabilitation programme includes a preoperative exercise intervention complemented by nutritional and psychological support. Patients will be randomized to either an individualized, progressive preoperative exercise and education programme or to usual care. Those in the control group will receive written recommendations on exercise and nutrition. General physical activity and dietary behaviour will be assessed in both groups throughout the study period, and programme adherence will be documented for per-protocol analysis. In the preparatory phase of the trial (months 1-6), standardized exercise materials and an exercise SOP will be developed and provided to all participating centers. Consistent implementation will be ensured through uniform delivery of the exercise programme and weekly video conferences to monitor fidelity and Borg scale application.
The overall aim of this prehabilitation programme is to maximize the physical capacity (in regards of strength and endurance) within the given time frame. The supervised progressive exercise programme will be conducted and supervised by a professional sport therapist, consisting of three 50-min sessions per week. Each session will be divided in (i) a resistance exercise part, aiming to increase patients' strength and (ii) an endurance part aiming to improve patients' cardio-respiratory fitness. A home-based walking programme (as per usual care) will be conducted in the intervention group on the days, when they are not attending the prehabilitation programme.
Outcome measures will be evaluated by a blinded endpoint committee consisting of two independent researchers, with inter-observer variability assessed and reported. The primary endpoint is the incidence of major postoperative complications (Clavien-Dindo grade III-V), a validated and widely used outcome strongly associated with surgical risk and five-year survival in cancer patients. This endpoint will be analyzed within a clinically relevant time frame of 30 days after surgery or until discharge, as preliminary data indicate that most grade III-V complications occur during this period. Previous prehabilitation studies have demonstrated feasibility and improvements in functional capacity, and recent randomized trials suggest a reduction in complications. However, these studies largely focus on colorectal cancer, whereas patients with upper gastrointestinal malignancies-who face complication rates of 30-40%-are the focus of the present trial. Secondary endpoints include the Comprehensive Complication Index, specific medical complications, ICU and hospital length of stay, days at home after surgery, initiation of adjuvant therapy, cost-effectiveness, functional capacity, quality of life, and perioperative anxiety and depression.
In addition to all endpoints mentioned above, serum / peripheral blood mononuclear cells (PBMCs) and tumour material will be stored for mechanistic analysis (e.g. inflammation, wound healing, immune function) in secondary step. Putative biological mechanisms attributed to the effectiveness of prehabilitation include the pleiotropic effects of exercise, which through numerous physiological systems may impact surgical outcome. Exercise as part of prehabilitation stimulates bone-marrow derived cells improving vascular function and wound healing. An episode of maximal exercise mobilized progenitor populations into the peripheral circulation in some patients and this was associated with fewer postoperative complications. Exercise also generates erythropoietin, increasing red cell counts and stimulates natural killer cell production, which may modulate the tumor defense response. Recent evidence suggests that preoperative exercise may down-stage tumor grade. These beneficial effects may be driven by exercise-induced anti-inflammatory pathways as well as by a mobilization and activation of tumor-competitive lymphocytes. The above mechanisms will be investigated in consecutive analyses with regard to the research topics: 1. endothelial regeneration, 2. inflammation 3. tumor defense and 4. cognitive function. An additional research proposal will be submitted in order to clarify on the specific translational mechanisms (i.e. exercise-stimulation of natural killer cells for clinical tumor defense).
- Conditions
- Cancer Surgery, Prehabilitation
- Being tested
- Multimodal Prehabilitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multimodal PrehabilitationProcedure or surgery
Multimodal prehabilitation includes preoperative exercise (HIIT), nutritional optimization and psychological support
| Study group | Role | What they receive |
|---|---|---|
| Prehabilitation | Experimental | Multimodal Prehabilitation Receives: Procedure: Multimodal Prehabilitation |
| Control Group | No intervention | Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative complications defined as Clavien-Dindo Classification grade III-V
Measured: During hospital stay until the day of discharge (assessed up to five days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start1 Jul 2026 (estimated)
- Primary completion1 Jul 2028 (estimated)
- Study completion1 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital of Cologne
- Sponsor type
- University, hospital or other
- Collaborators
- Charity, University of Berlin, Johannes Gutenberg University Mainz, University Hospital Tuebingen
- Responsible party
- Principal investigator, Prof. Robert Schier, University Hospital of Cologne
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07389746
- Sponsor's protocol ID
- SCHI1149/7-1
- Other IDs
- DFG Project#: 558914691
- Acronym
- PREHAB
- Status last verified
- Jan 2026
- First submitted
- 28 Jan 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Not permitted by ethical protocol
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multimodal Prehabilitation Reduces Postoperative Complications in High Risk Patients Undergoing Major Gastrointestinal Cancer Surgery
- ClinicalTrials.gov ID
- NCT07389746
- Acronym / sponsor ID
- PREHAB / SCHI1149/7-1
- Conditions
- Cancer Surgery, Prehabilitation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University Hospital of CologneUniversity, hospital or other
- Collaborators
- Charity, University of Berlin, Johannes Gutenberg University Mainz, University Hospital Tuebingen
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 1 Jul 2028 (estimated)
- Study completion
- 1 Jan 2029 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this prospective, randomized, controlled trial patients undergoing major gastrointestinal cancer surgery will be exercised (intervention group) 4 weeks before surgery with a high-intensity interval training (HIIT). They will also receive a specialized nutrition therapy and psychological support (multimodal prehabilitation). Aim of this study is to find out if the prehabilitation group is more resilient to postoperative complications when compared to the control group that will receive standard of care. Another goal is to unravel the underlying mechanisms that are stimulated by exercise like enhancing vascular function, improving immune system response, strengthen cellular tumor defense and optimizing neurological outcome.
Detailed description
Postoperative complications leading to death represent the third leading cause of mortality worldwide, equating to roughly one in 13 deaths and forming what has been termed a hidden pandemic. Analysis of the ACS NSQIP database further illustrates this impact, revealing that 19% of surgical patients had not returned home within 30 days. The severity of these complications is strongly associated with long-term survival outcomes. However, for individuals with advanced or recurrent gastrointestinal cancers-including pelvic, peritoneal, oesophageal, hepatic, gastric, and pancreatic disease-complete surgical resection remains the sole potentially curative treatment. In Germany alone, approximately 85,000 patients undergo major gastrointestinal cancer surgery annually, making complication reduction a key clinical goal. This multicenter German trial is the first to comprehensively integrate exercise, nutrition, psychological support, and patient education into a modern multimodal prehabilitation strategy.
The main outcome measure of this trial is the incidence of severe postoperative complications defined as Clavien-Dindo grade III-V. The central hypothesis is that prehabilitation decreases postoperative complications and thus improves prognosis and survival. The intended study population includes patients with substantial comorbidities who face a high risk of complications, elevated healthcare costs, and poor cancer outcomes, often due to impaired physiological fitness and failure to complete intended oncological therapy.
Inclusion criteria are:
- age ≥18/ ≤80 years
- elective major abdominal cancer surgery (pelvic exenteration, cytoreductive surgery, oesophagectomy, transhiatal gastrectomy, hepatectomy, pancreatectomy, rectum resection)
- Duke Activity Status Index (DASI) score <40
- high risk for surgical complications: => presence of comorbid disease as one or more of the following:
- known or documented history of coronary artery disease
- known or documented history of heart failure or brain-derived natriuretic peptide (BNP) >400pg/mL
- high risk of pulmonary complications as documented by Ariscat score >4434
- diabetes currently treated with an oral hypoglycemic agent and/or insulin
- preoperative serum creatinine >200 μmol/l
- morbid obesity with body mass index (BMI) ≥35 kg/m2
- preoperative deconditioning as confirmed by six-minute walk test (6-MWT) <400 meters or by cardiopulmonary exercise testing (CPET) derived parameters (either anaerobic threshold (if done) <12 ml/kg/min, peak oxygen consumption (VO2) <16 mL/kg/min, peak VO2<710 mL/m2, or Ve/VCO2 [ventilator equivalents for carbon dioxide] >35)
- schedule allowing for at least 4 weeks for intervention with multimodal prehabilitation prior to surgery and patient's willingness to exercise
Exclusion criteria are:
- non-elective surgery
- unstable cardiac or respiratory disease
- locomotor limitations precluding exercise training, including severe deconditioning and frailty as reflected by inability to complete CPET test or peak VO2 <10 ml/kg/min
- cognitive deterioration impeding adherence to the programme
The prehabilitation programme includes a preoperative exercise intervention complemented by nutritional and psychological support. Patients will be randomized to either an individualized, progressive preoperative exercise and education programme or to usual care. Those in the control group will receive written recommendations on exercise and nutrition. General physical activity and dietary behaviour will be assessed in both groups throughout the study period, and programme adherence will be documented for per-protocol analysis. In the preparatory phase of the trial (months 1-6), standardized exercise materials and an exercise SOP will be developed and provided to all participating centers. Consistent implementation will be ensured through uniform delivery of the exercise programme and weekly video conferences to monitor fidelity and Borg scale application.
The overall aim of this prehabilitation programme is to maximize the physical capacity (in regards of strength and endurance) within the given time frame. The supervised progressive exercise programme will be conducted and supervised by a professional sport therapist, consisting of three 50-min sessions per week. Each session will be divided in (i) a resistance exercise part, aiming to increase patients' strength and (ii) an endurance part aiming to improve patients' cardio-respiratory fitness. A home-based walking programme (as per usual care) will be conducted in the intervention group on the days, when they are not attending the prehabilitation programme.
Outcome measures will be evaluated by a blinded endpoint committee consisting of two independent researchers, with inter-observer variability assessed and reported. The primary endpoint is the incidence of major postoperative complications (Clavien-Dindo grade III-V), a validated and widely used outcome strongly associated with surgical risk and five-year survival in cancer patients. This endpoint will be analyzed within a clinically relevant time frame of 30 days after surgery or until discharge, as preliminary data indicate that most grade III-V complications occur during this period. Previous prehabilitation studies have demonstrated feasibility and improvements in functional capacity, and recent randomized trials suggest a reduction in complications. However, these studies largely focus on colorectal cancer, whereas patients with upper gastrointestinal malignancies-who face complication rates of 30-40%-are the focus of the present trial. Secondary endpoints include the Comprehensive Complication Index, specific medical complications, ICU and hospital length of stay, days at home after surgery, initiation of adjuvant therapy, cost-effectiveness, functional capacity, quality of life, and perioperative anxiety and depression.
In addition to all endpoints mentioned above, serum / peripheral blood mononuclear cells (PBMCs) and tumour material will be stored for mechanistic analysis (e.g. inflammation, wound healing, immune function) in secondary step. Putative biological mechanisms attributed to the effectiveness of prehabilitation include the pleiotropic effects of exercise, which through numerous physiological systems may impact surgical outcome. Exercise as part of prehabilitation stimulates bone-marrow derived cells improving vascular function and wound healing. An episode of maximal exercise mobilized progenitor populations into the peripheral circulation in some patients and this was associated with fewer postoperative complications. Exercise also generates erythropoietin, increasing red cell counts and stimulates natural killer cell production, which may modulate the tumor defense response. Recent evidence suggests that preoperative exercise may down-stage tumor grade. These beneficial effects may be driven by exercise-induced anti-inflammatory pathways as well as by a mobilization and activation of tumor-competitive lymphocytes. The above mechanisms will be investigated in consecutive analyses with regard to the research topics: 1. endothelial regeneration, 2. inflammation 3. tumor defense and 4. cognitive function. An additional research proposal will be submitted in order to clarify on the specific translational mechanisms (i.e. exercise-stimulation of natural killer cells for clinical tumor defense).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prehabilitation | Experimental | Procedure: Multimodal PrehabilitationMultimodal Prehabilitation |
| Control Group | No intervention | –Standard of Care |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Candidate to elective major gastrointestinal cancer surgery (pelvic exenteration, cytoreductive surgery, oesophagectomy, transhiatal gastrectomy, hepatectomy, pancreatectomy, rectum resection)
- High risk for surgical complications defined by presence of comorbid disease such as deconditioning, heart disease, diabetes, renal impairment or morbid obesity
- Duke Activity Status Index score (DASI) <402
- Schedule allowing for at least 4 weeks for intervention with multimodal prehabilitation prior to surgery / willingness to exercise
Key exclusion criteria (5 listed)
- Non-elective surgery
- Unstable cardiac or respiratory disease
- Locomotor limitations precluding exercise training
- Cognitive deterioration impeding adherence to the programme
- Enrolment in other research studies affecting study endpoint
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multimodal PrehabilitationMultimodal prehabilitation includes preoperative exercise (HIIT), nutritional optimization and psychological support | Procedure or surgery | Prehabilitation |
Primary outcome
Postoperative complications defined as Clavien-Dindo Classification grade III-V
Time frame: During hospital stay until the day of discharge (assessed up to five days)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- Individual participant dataSharing planned: No. Not permitted by ethical protocol
Related trials for Cancer Surgery
Recruiting
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.
Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H)
RecruitingPhase 3
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Non-Small Cell Lung Cancer
RecruitingPhase 3
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Lung Non-Small Cell Carcinoma
RecruitingObservational study
Carotid Doppler Changes After Passive Leg Raising for Prediction of Post-Induction Hypotension in Gastrointestinal Tumor Surgery
Post-induction Hypotension (PIH), Gastrointestinal Tumor Surgery
Not yet recruiting
GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma
Recurrent Glioma (Glioblastoma Multiforme)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multimodal Prehabilitation in people with Cancer Surgery and Prehabilitation, run by University Hospital of Cologne at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Robert Schier, MD, PhD (0049-178-8210611, robert.schier@uk-koeln.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative complications defined as Clavien-Dindo Classification grade III-V (time frame: During hospital stay until the day of discharge (assessed up to five days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.